Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease

Anita G. Koshy(Beth Israel Deaconess Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Haesook Kim(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Corey Cutler(Harvard University), Vincent T. Ho(Dana-Farber Cancer Institute), Poorva Bindal(Beth Israel Deaconess Medical Center), Mahasweta Gooptu(Harvard University), Susan T. Stephenson, David Avigan(Beth Israel Deaconess Medical Center), Joseph H. Antin(Dana-Farber Cancer Institute), Hassan El Banna(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Pavania Elavalakanar(Beth Israel Deaconess Medical Center), Emma Logan(Beth Israel Deaconess Medical Center), Giulia Cheloni(Beth Israel Deaconess Medical Center), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Jessica Liegel(Beth Israel Deaconess Medical Center), Sarah Nikiforow(Otsuka (Japan))
Transplantation and Cellular Therapy
March 1, 2022
10.1016/s2666-6367(22)00193-2
Cited by 0

Related Papers

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k